The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV | Annals of Internal Medicine
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t sign in? Forgot your username? View all available purchase options and get full access to this article. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. [PMID: 27633186] doi: 10.1056/NEJMoa1607141 Newsome PN, Buchholtz K, Cusi K, et